Business
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
OSAKA, Japan & WALTHAM, Mass., December 06, 2025--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL.
About this update from Ono Pharmaceutical Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":773,"height":250,"url":"https://media.zenfs.com/en/business-wire.com/811f87dac0e7f1fb7ae1bbe6449bd15e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kDSq6WxcJISxQw4stvc05g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/811f87dac0e7f1fb7ae1bbe6449bd15e","width":773,"height":250},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/GndpZL_Bl5.y4NCSh2OEaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE1NDY7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/811f87dac0e7f1fb7ae1bbe6449bd15e","width":773,"height":250}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/82b9620095cf0518e6171dd25e7bca1f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HZ5Jue5IYvsJyFFxN.Ri_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/82b9620095cf0518e6171dd25e7bca1f","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/S6xCAvA7chcEHc8vlgdz2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/82b9620095cf0518e6171dd25e7bca1f","width":1024,"height":512}}},{"type":"list","items":[{"val":[{"type":"text","content":"Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin","length":151,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Sapablursen was generally safe and well tolerated","length":49,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Results support further development of sapablursen in a Phase 3 study","length":69,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":269,"olType":false},{"type":"text","content":"OSAKA, Japan & WALTHAM, Mass., December 06, 2025--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced the oral presentation of positive results from the Phase 2a IMPRSSIO...